Spain’s Grifols has agreed to buy US-based Talecris Biotherapeutics, which makes plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products.
Talecris is the manufacturer of Prolastin, the augmentation therapy for Alpha-1 Antitrypsin Deficiency. Grifols also manufactures an augmentation therapy, distributed in some European countries.
The deal would increase healthcare company Grifols’ global presence by adding market share in United States and Canada to its leading position in Europe, helping it compete better with rivals such as Baxter International and Australia’s CSL.
Grifols said today it expects about $230 million in “annual synergies” from the deal, which has been unanimously approved by both companies’ boards and recommended to their shareholders.